Although this June may look and feel different from years past, we’re just as excited to spread awareness together with the myasthenia gravis (MG) community in celebration of Myasthenia Gravis (MG) Awareness Month. In light of the impact coronavirus is having on people around the world, especially people with MG who may be immunocompromised, we’re looking forward to connecting and celebrating in a virtual way.

Over the last several weeks, UCB has shared deep concern and sadness about the state of racial injustice and heinous acts of violence against Black Americans happening in our country. We remain committed to living our Patient Value Principles to respect all people and to embrace diversity of thought, experience, and background. At UCB, we do not tolerate racism and racial injustice in any form.

UCB has been making ongoing adjustments to ensure continuous care for patients, including people living with immune-mediated inflammatory diseases during this time of great isolation. Hear more from UCB's Head of U.S. Immunology, Camille Lee, about our efforts to better support patients during this time.

• Data from the Phase 3 BE VIVID and BE READY studies show that bimekizumab-treated patients with psoriasis achieved significant skin clearance at week 16, rapid response after one dose, and durability of response up to a year
• Results support the importance of selectively inhibiting IL-17F, in addition to IL-17A, with bimekizumab

At UCB, everything we do starts with one simple question: “How will this make a difference in the lives of people living with severe diseases?” This question is our motivation, inspiration and what challenges us to stay focused on what will ultimately benefit the patients we serve. Read more from Camille Lee, Head of U.S. Immunology, about how UCB is working to empower patients impacted by immuno-dermatological conditions.

• Underlines UCB’s leadership in epilepsy by adding Staccato^® Alprazolam, a drug-device-combination with the potential to be the first on-demand, single-use treatment to rapidly terminate an active epileptic seizure

Congratulations to Andrea Loewendorf – Head, Market Access and Innovation Strategy, Neurology and Jessica Williamson, PhD – Protein Production Lead for their recognition as a Healthcare Businesswomen's Association (HBA) Rising Stars for 2020!

At UCB, we are using our passion and expertise to address gaps in post-fracture care to provide patients the support they need. This Osteoporosis Awareness Month, read from Alison Kocanda, Head of U.S. Bone, as she shares how UCB is supporting patients through education and resources.

Every three seconds - that is how often it is estimated that a fragility fracture occurs. Although nearly 9 million fractures occur annually worldwide, oftentimes people think fragile bones are an inevitable part of getting older, but a fracture may more commonly be the result of an underlying condition: osteoporosis. This May for Osteoporosis Awareness Month, we’re highlighting things to know about osteoporosis and our commitment to addressing the gaps impacting those living with the disease.

Patients are at the heart of everything we do, and UCB is committed to helping those impacted by the novel coronavirus, COVID-19. This includes helping patients maintain access to and answering any questions about UCB medicines, as well as putting patient and community care first in all our actions during these uncertain times.